Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Ideaya Highlights

 
Investor Presentation
Recent News
Nov 4, 2024

Enrollment in darovasertib + crizotinib 1L HLA-A2(-) MUM potential Ph2/3 registration-enabling trial is ahead of schedule and has exceeded 150 patients Successful FDA Type C meeting and targeting...

Nov 1, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on October 31, 2024, the...

Oct 28, 2024

IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5th potential first-in-class clinical program

All Releases

Events
Wednesday, October 23, 2024 - Friday, October 25, 2024

 

 

 

Oral presentation details:

Presenter: Dr. Benjamin Herzberg, MD, Assistant Professor, Columbia University
Title: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Abstract #: 501 LBA
Session: Plenary Session 7, Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date and Time: Friday, October 25, 2024 at 3:54pm CEST
Download Presentation

Poster presentation details:

Author: Garbett, D. et al.
Title: The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
Poster Number: PB204
Session Title: Combination Therapies
Date and Time: Thursday, October 24, 2024, 9:00am - 5:30pm CEST, Exhibition Hall
Download Presentation

Author: Munoz, D. et al.
Title: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities
Poster Number: PB337
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Date and Time: Friday, October 25, 2024, 9:00am - 3:00pm CEST, Exhibition Hall
Download Presentation

Monday, September 23, 2024
8:00am EDT

Pre-registration is available through the following link:
https://lifescievents.com/event/ideaya-3/

All Events

Stock Info
NASDAQIDYA

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
650-443-6214
investor@ideayabio.com

Subscribe to email alerts
* Required Fields
WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS

Close Menu